|
06 Jul 2022 |
Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant
|
|
29 Jun 2022 |
Icosavax Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV
|
|
25 Jun 2022 |
Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate
|
|
25 Jun 2022 |
Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine
|
|
25 Jun 2022 |
Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001
|
|
24 Jun 2022 |
Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
|
|
23 Jun 2022 |
U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children
|
|
21 Jun 2022 |
Affinivax Presents Data for Enhanced Protection Against Serotype 3 in Next-Generation Pneumococcal Vaccine
|
|
21 Jun 2022 |
PharmaJet Partner, Nykode Therapeutics, Announces Positive Interim Results in HPV+ Cervical Cancer Phase 2 Trial
|
|
21 Jun 2022 |
Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults
|
|
20 Jun 2022 |
Ultimovacs’ UV1 cancer vaccine shows strong overall survival in malignant melanoma phase I trial
|
|
13 Jun 2022 |
Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron
|
|
11 Jun 2022 |
GSK announces positive pivotal phase III data for its respiratory syncytial virus (RSV) vaccine candidate for older adults
|
|
06 Jun 2022 |
GSK announces US FDA approval of Priorix for the prevention of measles, mumps and rubella in individuals 12 months of age and older
|
|
06 Jun 2022 |
Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for glioblastoma, at ASCO 2022
|
|
06 Jun 2022 |
Nouscom Announces Positive Full Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022
|
|
06 Jun 2022 |
Positive Phase 1 Data from mRNA-based Individualized Neoantigen Specific Immunotherapy in Patients with Resected Pancreatic Cancer presented at ASCO
|
|
05 Jun 2022 |
HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO
|
|
01 Jun 2022 |
Clover Doses First Participants in Phase 1 Trial with SCB-2020S, a Potentially Broadly Protective Chimeric COVID-19 Vaccine Candidate
|
|
30 May 2022 |
RhoVac's phase IIb study in prostate cancer , BRaVac, failed to meet its primary endpoint
|
|
27 May 2022 |
Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development
|
|
26 May 2022 |
Daiichi Sankyo Announces Development Progress of mRNA COVID-19 Vaccine (DS-5670) in Japan
|
|
23 May 2022 |
RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis
|
|
23 May 2022 |
Anokion Announces Positive Data from Phase 1 ACeD Clinical Trial Evaluating KAN-101 as a Treatment for Celiac Disease Presented in a Plenary Session at DDW 2022
|
|
23 May 2022 |
Vaxzevria approved in the EU as third dose booster against COVID-19
|
